Predictors of recurrent specialized intestinal metaplasia after complete laser ablation

American Journal of Gastroenterology

Volumn 98, Issue 9, 2003, Pages 1945-1951

  Fisher, Robert S ^a   Bromer, Matthew Q ^b   Thomas, Rebecca M ^b   Cohen, Sidney ^b   Krevsky, Benjamin ^b   Horwitz, Brenda ^b   Glazier, Kenneth D ^b   Das, Koushik ^b   Das, Kiron M ^b  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; COLON EPITHELIUM PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; APPARATUS; ARTICLE; BARRETT ESOPHAGUS; CARDIA; CLINICAL ARTICLE; ENDOSCOPIC SURGERY; ESOPHAGUS BIOPSY; ESOPHAGUS PERFORATION; ESOPHAGUS RESECTION; ESOPHAGUS STRICTURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; LASER SURGERY; MALE; NEODYMIUM LASER; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SQUAMOUS EPITHELIUM; STOMACH MUCOSA; UPPER GASTROINTESTINAL BLEEDING;

EID: 0141682768     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07628.x     Document Type: Article

References (40)

1. Barrett NR. The lower esophagus lined by columnar epithelium. Surgery 1957;41:881-94.
2. Spechler SJ, Goyal RK. The columnar lined esophagus, intestinal metaplasia and Norman Barrett. Gastroenterology 1996;110:614-21.
3. Sampliner RE. The Practice Parameters Committee of the American College of Gastroenterology practice guidelines on the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 1998;93:1028-32.
4. Goyal RK, Hamilton FA. Columnar lined (Barrett's) esophagus: Highlights of the NIDDK/VHA conference. Clinician 1999;17:1-30.
5. Lagergren J, Bergstrom R, Lingren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
6. Cameron AJ, Ott BJ, Payne WJ. Barrett's oesophagus: Incidence of adenocarcinoma during long-term follow-up. Gut 1983;24:A1007-8.
7. Yang PC, Davis S. Incidence of cancer of the esophagus in the United States by histologic type. Cancer 1988;61:612-7.
8. Pera M, Cameron AJ, Trostek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-3.
9. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
10. O'Conner JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus. Am J Gastroenterol 1999;8:2037-42.
11. Pera M. Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent Res Cancer Res 2000;155:1-14.
12. Hirota WK, Longhney TM, Lazas DJ, et al. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data. Gastroenterology 1999;116:277-85.
13. Sampliner RE, Hixson LJ, Fennerty MB, Garawal HS. Regression of Barrett's esophagus by laser ablation in an anacid environment. Dig Dis Sci 1993;38:365-8.
14. Berenson MM, Johnson TD, Markowitz NR, et al. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology 1993;104:1686-91.
15. Overholt BF, Panjehpour M. Photodynamic therapy for Barrett's esophagus: Clinical update. Am J Gastroenterol 1996;91:1719-23.
16. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998;114:448-55.
17. Wong KK. Photodynamic therapy of Barrett's esophagus. Gastroenterol Endosc Clin North Am 2000;10:409-19.
18. Sampliner RE, Fennerty B, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation. Preliminary results. Gastrointest Endosc 1996;44:532-5.
19. Bryne JP, Armstrong GR, Attarwal SEA. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol 1998;93:1810-5.
20. Sampliner RE. Ablative therapies for the columnar-lined esophagus. Gastroenterol Clin North Am 1997;26:685-94.
21. Vanden Bougert J, Van Hillegersberg R, Siersema PD, et al. Endo-scopic ablation therapy for Barrett's esophagus with high-grade dysplasia: A review. Am J Gastroenterol 1999;94:1153-90.
22. Haag S, Nandarkar, Talley N. Regression of Barrett's esophagus: The role of acid suppression, surgery and ablative methods. Gastrointest Endosc 1999;80:229-40.
23. Garewal H, Ramsey L, Sharma P, et al. Biomarker studies in reversed Barrett's esophagus. Am J Gastroenterol 1999;94:2829-33.
24. Krishnadeth KK, Wang KK, Tamiguchi K, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000;119:624-30.
25. Das KM, Sakamaki S, Vecchi M, Diamond B. The production and characterization of monoclonal antibodies to a human colonic antigen associated with ulcerative colitis: Cellular localization of the antigen by using the monoclonal antibody. J Immunol 1987;139:77-84.
26. Kesari KV, Yoshigaki N, Geng X, et al. Extemalization of tropomyosin isoform 5 in colon epithelial cells. Clin Exp Immunol 1999;118:219-27.
27. Das KM, Prasad I, Garla S, Amenta PS. Detection of a shared colon epithelial epitope on Barrett's epithelium by a novel monoclonal antibody. Ann Intern Med 1994;120:753-6.
28. Glickman JN, Wong H, Das KM, et al. Phenotype of Barrett's esophagus and intestinal metaplasia of the distal esophagus and gastroesophageal Junction. Am J Surg Pathol 2001;25:87-94.
29. Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high dose omeprazole. Gastrointest Endosc 2000;51:65-68.
30. Gore S, Healey CJ, Sutton R, et al. Regression of columnar lined (Barrett's) esophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993;7:623-8.
31. Sampliner RE. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994;89:1844-8.
32. Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's esophagus. Aliment Pharmacol Ther 1998;12:893-7.
33. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment: A randomized double-blind study. Gut 1999;45:489-94.
34. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996;44:700-5.
35. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: Results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999;13:1205-9.
36. Griffel LH, Amenta PS, Das KM. Use of a novel monoclonal antibody in diagnosis of Barrett's esophagus. Dig Dis Sci 2000;45:40-8.
37. Griffel LH, Weston AP, Kardnik NA, et al. Early diagnosis of short segment Barrett's esophagus (SSBE) using an immunohistochemical marker: An interinstitutional blinded study. Gastroenterology 1998;114:A571.
38. Chandrosoma PT, Der R, Dalton P, et al. Distribution and significance of epithelium types in columnar lined esophagus. Am J Surg Pathol 2001;25:1188-93.
39. Biddlestone LR, Barham CP, Wilkinson SP, et al. The histopathology of treated Barrett's esophagus: Squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 1998;22:239-45.
40. Laethem JL, Peny MO, Salmon J, et al. Intramucosal adenocarcinoma arising under squamous re-epithelization of Barrett's oesophagus. Gut 2000;46:574-7.